Table 1.
Clinical and laboratory results at baseline and after treatment in 91 patients with visceral leishmaniasis. Values are mean (SE) unless stated otherwise
| Single dose (n=46)
|
5 daily doses (n=45)
|
||||
|---|---|---|---|---|---|
| Day 0 | Day 15* | Day 0 | Day 19* | ||
| Age (years)† | 17 (2) | 18 (2) | |||
| No (%) of men | 30 (65) | 29 (64) | |||
| No (%) previously given antimony | 22 (48) | 14 (31) | |||
| Duration of illness (months) | 3.6 (0.4) | 3.3 (0.5) | |||
| Splenic aspirate score | 1.8 (0.1) | 0.2 (0.02) | 2.0 (0.20) | 2 (0.02) | |
| Weight (kg) | 27 (2) | 27 (2) | 29 (2) | 30 (2) | |
| Spleen size (cm) | 7.8 (0.6) | 3.0 (0.4) | 7.2 (0.7) | 3.2 (0.5) | |
| Haemoglobin (g/l) | 70 (3) | 89 (2) | 78 (2) | 97 (2) | |
| White blood cells (×109/l) | 3.6 (0.3) | 6.3 (0.3) | 3.8 (0.2) | 7.0 (0.4) | |
| Platelet count (×109/l) | 121 (7) | 247 (12) | 153 (10) | 292 (15) | |
| Blood urea nitrogen (mmol/l) | 3.6 (0.4) | 3.9 (0.4) | 3.6 (0.4) | 3.9 (0.4) | |
| Creatinine (μmol/l) | 62 (3.5) | 62 (2.7) | 62 (3.5) | 62 (2.7) | |
*
Responses were measured 14 days after last treatment—day 15 for single dose and day 19 for five dose group.
†
24 participants in each group were children (⩽12 years old).